Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia

Johanna Waidhauser, Anne Bornemann, Martin Trepel, Bruno Märkl

ORCID number: Johanna Waidhauser (0000-0003-2776-1590); Anne Bornemann (0000-0002-1798-1971); Martin Trepel (0000-0002-3358-6568); Bruno Märkl (0000-0002-7704-850X).

Author contributions: Waidhauser J performed literature research, collected and analyzed the data, performed statistical analysis and drafted the manuscript. Bornemann A performed literature research. Trepel M provided analytical oversight and revised the manuscript. Märkl B designed the review, was involved in literature research and statistical analysis and revised the manuscript.

Conflict-of-interest statement: All authors declare that no conflicting interests (including but not limited to commercial, personal, political, intellectual or religious interests) exist.

Data sharing statement: Statistical code, and dataset available from the corresponding author at Dryad repository, who will provide a permanent, citable and open-access home for the dataset.

PRISMA 2009 Checklist statement: The guidelines of the Priisma 2009 Statement have been adopted.

Abstract

BACKGROUND
In recent years, increasing evidence of second neoplasms associated with gastrointestinal stromal tumors (GIST) has been found. Numerous case reports, mostly retrospective studies and a few reviews, have been published. To our knowledge, however, no systematic review or meta-analysis of the existing data has been performed so far.

AIM
To prepare a compilation, as complete as possible, of all reported second tumor entities that have been described in association with GIST and to systematically analyze the published studies with regard to frequency, localization, and types of GIST-associated neoplasms.

METHODS
The MEDLINE and EBSCO databases were searched for a combination of the keywords GIST/secondary, synchronous, coincident/tumor, neoplasm, and relevant publications were selected by two independent authors.

RESULTS
Initially, 3042 publications were found. After deletion of duplicates, 1631 remained, and 130 papers were selected; 22 of these were original studies with a minimum of 20 patients, and 108 were case reports. In the 22 selected studies, comprising a total number of 12050 patients, an overall rate of GIST-associated neoplasias of 20% could be calculated. Most second neoplasias were found in the gastrointestinal tract (32%) and in the male and female urogenital tract (30%). The specific risk scores of GISTs associated with other tumors were significantly lower than those without associated neoplasias.
CONCLUSION

In this first systematic review, we could confirm previously reported findings of a more than coincidental association between GIST and other neoplasias. The question whether there is an underlying causal association will need further investigation. Our data suggest that even GIST with a very low risk of disease progression should prompt screening for second neoplasia and subsequent frequent controls or extended staging.

Key words: Gastrointestinal stromal tumor; Associated; Secondary; Neoplasia; Tumor

Core tip: Gastrointestinal stromal tumors (GIST) associated neoplasms have been previously reported to occur with a more than coincidental frequency. Numerous case reports, mostly retrospective studies and a few reviews have been published on this topic. In this, to our knowledge, first systematic review we analyzed 108 case reports and 22 retrospective and prospective studies with a total of 12050 patients. An overall rate of GIST-associated neoplasias of 20% could be calculated. Most second neoplasias were found in the gastrointestinal tract (32%) and in the male and female urogenital tract (30%).

INTRODUCTION

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract. Yearly incidence rates vary from 4.3 to 22 per million in different geographic regions, which may at least in part be caused by changing and improving diagnostic criteria and a lack of established GIST registries. In most studies, however, the yearly incidence is indicated as 10 to 15 per million[1], fulfilling the criterion of a rare disease. Median age at diagnosis is reported to be between 60 and 69 years in most studies[1,2]. GIST are considered to develop from interstitial cells of Cajal (ICC), which play an important role in autonomous gastrointestinal movement[3]. The most common localization of GIST is the stomach, followed by other gastrointestinal tract localizations[2,4].

Several driver mutations have been identified as playing an essential role in the development of GIST. The most frequent mutation can be found in the tyrosine kinase receptor c-kit (c-KIT), which accounts for 70%-80% of GIST[5-7] and is nowadays the most important target of medical tumor therapy in GIST patients. Other relevant mutations can be observed in the platelet-derived growth factor receptor alpha (PDGFR-α) in 5%-10%[5-7] and, in rare cases, in other genes such as neurofibromin 1 (NF1), succinate dehydrogenase (SDH), or BRAF[6,8].

GIST can occur in the setting of genetic syndromes such as neurofibromatosis 1[9], Carney triad[10], or familial GIST[11] and, in these cases, frequently come along with other benign or malignant neoplasias. In recent years, though, there has been increasing evidence of second neoplasia in patients with sporadic GIST[12-15]. Several retrospective studies and case series have been published on this topic, complemented by many case reports and a few reviews, but so far to our knowledge, no meta-analysis or systematic reviews have been conducted. The aim of this first systematic review is to prepare a compilation, as complete as possible, of all reported second tumor entities that have been described in association with GIST and to systematically analyze the published studies with regard to frequency, localization, and types of GIST-associated neoplasms.

MATERIALS AND METHODS
Literature research
We performed a literature search in the MEDLINE and EBSCO databases, using the keywords GIST/secondary, synchronous, coincident/tumor, neoplasm. All results were transferred to the citation manager Endnote® and duplicates were deleted. The remaining results were screened by two authors with regard to suitable topic, language, and publication standard. Discrepancies were resolved after discussion with a senior third author. Case reports and case series/studies in English or German were included. Only data that was fully published was eligible. Syndromic settings as familial GIST or neurofibromatosis were excluded as well as cases involving children. Studies had to include at least 20 patients, and studies that investigated only one specific kind of second neoplasm were excluded. Second neoplasms were considered regardless of the time frame between their occurrence and the occurrence of GIST. Malignant as well as benign second neoplasms were selected. In addition, the bibliographies of all selected papers that were published between 2016 and 2019 were screened for suitable references, as were the six published reviews on this topic.

Statistical analysis
For statistical calculations, we used SigmaPlot 13.0 (Systat, Erkrath, Germany) and Microsoft Excel (Microsoft Office 16). The chi-squared test was performed for testing the relationship between two categorical variables. A \( P \)-value of < 0.05 was considered significant.

PROSPERO registration
Before starting the literature research, a registration of this systematic review in the international Prospective Register of Systematic Reviews (PROSPERO, registration number CRD42019122784) was performed.

RESULTS
The literature search revealed a total of 3042 publications before February 2019. After deletion of duplicates, 1631 papers remained. Screening by the two authors (Waidhauser J and Bornemann A) resulted in 126 eligible papers. In addition, one study on 188 GIST patients that was performed at our institute by Mayr et al[15] and had not been published by the time of the literature search was included. Of the 130 selected publications, 108 were case reports and 22 were case series or retrospective and prospective studies (Figure 1).

All additional neoplasms that were reported in the case reports are listed in Table 1. The most frequent types were gastric and colorectal adenocarcinomas.

Among the 22 retrospective and prospective studies, a total of 12050 patients were included. Basic information on these studies is summarized in Table 2. The number of patients in which an additional tumor to the GIST diagnosis was found was 2426 (20.1%). The median age at the diagnosis of GIST was 63 years in the total study population and 68 years in those patients with an additional tumor. The male-to-female ratio was 1.1:1 in the total population and 1.4:1 in the GIST with secondary neoplasia group. The chi-squared test revealed a significant difference for the sex distribution of \( P < 0.001 \) with a predominance of male gender in cases with associated neoplasm (Table 3).

Of 2248 patients, for whom the respective data were available, 253 benign (11%) and 1995 (89%) malignant neoplasias were reported, with the restriction that in some studies, only patients with malignant second neoplasias were included. Chronological considerations revealed that 50% (366 of 732) of second neoplasias occurred synchronously to GIST, 26% (187 of 732) occurred before GIST, and 24% (179 of 732) were diagnosed after GIST. Focusing on synchronous second neoplasias, a rate of 6% (366 of 5131) was detected among all GIST patients. Of these synchronous second neoplasias 77% (177 of 230) occurred in the GI-Tract and 7% (16 of 230) in the male and female urogenital tract. The distribution of different histological subtypes (spindle vs epithelioid vs mixed) revealed no differences between the GIST-only patients and the patients with another neoplasm (spindle: 78% vs 80%; epithelioid: 8% vs 6%; mixed: 14% vs 14%) (Table 4).

Figure 2 gives an overview of the different localizations of the GIST-associated neoplasias. The most common manifestation was seen in the gastrointestinal tract (32%), followed by urogenital and female genital tract (30%); 10% of additional tumors were found in the breast and 6% each in the lung and in the blood and lymphatic system.

Regarding the risk scores for disease progression or recurrence of GIST, there was a significantly \( (P < 0.001) \) higher proportion of very low- and low-risk GIST in patients.
with an additional tumor (65%) compared to the GIST-only group (35%), whereas in this latter group, the portion of intermediate and high-risk patients was higher (69% vs 31%). For calculation, we used the risk scores as they were applied in the different studies, which were most frequently those according to Fletcher et al\[4\] or Miettinen et al\[16\] (Table 5).

The mutational status of driver genes in patients with GIST and associated neoplasias was reported in only four of the 22 studies, with a total of 167 patients. These patients with GIST and second tumors showed mutations in exon 11 of the KIT gene in 69%, non-exon-11 mutations of the KIT gene in 6%, mutations in the PDGFR-α gene in 13%, and a "wildtype" status in 13%.

Data on follow-up was very heterogeneously reported or not available in most of the included studies, which is why even a descriptive analysis was not feasible.

DISCUSSION

In our systematic review, we detected a rate of 20.1% of second neoplasias in GIST patients, with the most frequent localization of associated tumors in the gastrointestinal tract and in the urogenital and female genital tract. Previously described rates of GIST-associated neoplasias varied between 11% and 50%\[13,17\]. The general probability of being diagnosed with cancer twice in a lifetime is estimated between 2% and 17% (syndromic settings or familial predisposition included)\[18\] or in other words with a chance of 1:9\[12,19\]. Compared to this number the rate of second neoplasias we found in GIST patients is obviously higher than expected. Several reasons can be considered accountable for the development of multiple tumors in one patient, for example, similar risk factors, environmental factors, or genetic predisposition, but also the higher likelihood of detection of another tumor within the examinations for staging or follow-up. In cases of sporadic GIST there are no definitely confirmed intrinsic risk factors or environmental factors. Genetic factors play a role in syndromes such as neurofibromatosis type I or Carney triad, but these patients were excluded in our study, and only patients with sporadic GIST were included. The occurrence of GIST-specific mutations such as in the e-KIT or PDGFRα gene that we found in the group of patients with GIST and second neoplasms were similar to those reported for GIST in general before\[5-7\].

The localization of GIST-associated neoplasias with the highest frequency in the gastrointestinal tract, the urogenital, and female genital tract is consistent with previously reported findings\[10,20\]. In addition to a possible common underlying predisposition, the probability of detecting even small GIST during staging examinations for gastrointestinal tract tumors might be higher than in cases of, for example, lung or head and neck tumors. This is might also be the explanation for the high rate of 77% of GI-tract localization in synchronous second neoplasias.

The median age of the total study population compared to the group of patients...
# Table 1  Case reports: Overview of tumor entities

| Tumor entity                                           | Ref.              |
|-------------------------------------------------------|-------------------|
| **Gastrointestinal Tract**                            |                   |
| Gastric adenocarcinoma                                | [29-55]           |
| Colorectal adenocarcinoma                             | [56-71]           |
| Gastric high grade IEN                                | [72]              |
| Esophagus SCC                                          | [73-75]           |
| Esophagus Small Cell Carcinoma                        | [76]              |
| Gastro-esophageal junction adenocarcinoma             | [77]              |
| Duodenum adenocarcinoma                               | [78]              |
| Papilla Vateri NET                                     | [79]              |
| Gastric Lipoma                                         | [80]              |
| Gastric NET                                            | [81-82]           |
| Duodenum NET                                           | [83]              |
| Ileum NET                                              | [84]              |
| Gastric Schwannoma                                     | [85]              |
| Colon NET                                              | [86]              |
| Jejunal Sarcomatoid Carcinoma                         | [87]              |
| Pancreas adenosquamous carcinoma                       | [88-90]           |
| Pancreas adenocarcinoma                                | [91-93]           |
| Pancreas NET                                           | [94-96]           |
| Hepatocellular carcinoma                              | [97]              |
| Cholangiocellular Carcinoma                           | [98]              |
| Perivascular Epithelial Cell Tumor Liver              | [99]              |
| **Urogenital Tract**                                   |                   |
| Renal Cell Carcinoma                                   | [100-102]         |
| Renal Chromophobe Cell Carcinoma                      | [103]             |
| Prostate Adenocarcinoma                               | [104-106]         |
| Transitional Cell Carcinoma Bladder                   | [107]             |
| **Female Genitale Tract**                             |                   |
| Ovarian Carcinoma                                      | [108]             |
| Ovarian Serous Adenocarcinoma                         | [109,110]         |
| Uterus Leiomyoma                                       | [111]             |
| **Breast**                                             |                   |
| Sarcoma                                                | [112]             |
| Invasive Ductal Carcinoma                             | [113]             |
| **Blood/ Lymphatic**                                  |                   |
| Acute Myeloid Leukemia                                 | [114-116]         |
| Acute Biphenotypic Leukemia                           | [117]             |
| Chronic Lymphoid Leukemia                             | [118]             |
| Low Grade B Cell Lymphoma Stomach                     | [119]             |
| Extramedial DLBCL                                      | [120]             |
| Burkitt Lymphoma                                       | [121]             |
| Mantle Cell Lymphoma Appendix                         | [122]             |
| MALT Lymphoma                                          | [123]             |
| Multiple Myeloma                                       | [124]             |
| **Head and Neck**                                     |                   |
| Oral Melanoma                                           | [125]             |
| Papillary Thyroid Carcinoma                           | [126]             |
| **Lung**                                               |                   |
| Adenocarcinoma                                         | [127-129]         |
| SCC                                                    | [130]             |
| NSCLC                                                  | [131]             |
| **Skin**                                               |                   |
who developed a second tumor showed a difference of five years at the time-point of GIST diagnosis, with the higher median age in the GIST with associated neoplasm group. A possible explanation for this finding could be the age-dependent risk increase for cancer in general\(^{14}\). Previously performed reviews on the topic of GIST and associated neoplasms mostly concentrated on the occurrence rate and localization of the associated tumors and, in some cases, on the outcome and follow-up\(^{20-24}\). Analysis of age or sex distribution have not been performed on larger numbers of patients. We found a significantly higher number of male patients who were diagnosed with GIST and a second neoplasia than in the total population of GIST patients. An equal sex distribution for GIST patients in general has been reported in the literature before\(^1\). Regarding the overall incidence of cancer worldwide, the sex distribution of patients diagnosed with cancer in 2018 is estimated at a male-to-female ratio of 1.1:1 (9.5 million new cases in men and 8.6 million new cases in women). Among gastrointestinal neoplasias, which were the most frequent GIST-associated neoplasias in our review, there is a difference in the worldwide incidence between men and women with a higher rate of gastrointestinal (GI) tumors diagnosed in men in 2018 (2.7 million cases in men vs 1.4 million cases in women)\(^{25}\). Whether there is a difference of distribution of the second neoplasias between sexes in our review population remains unclear. In most analyzed studies, the reported data was not sufficient to answer this question.

Several risk classification systems are used to assess the risk of disease progression or recurrence of GIST\(^\text{4,16}\). Most of them use the size, localization, and mitotic rate of GIST and are therefore, at least in part, comparable. By summarizing the risk categories in two groups (very low and low vs intermediate and high), we could find a significant difference between the GIST-only patients and those having GIST and another neoplasis by using the chi-squared test. The patients with GIST-associated neoplasias had lower risk scores, which might be due to a higher detection rate of even small GISTs with low risk scores in the setting of another neoplastic disease.

Since the establishment of targeted therapies for GIST with imatinib or second-line tyrosine kinase inhibitors, the prognosis even of advanced GIST has significantly improved\(^\text{26}\). On the other side, there is growing interest in the question of elevated risk of developing secondary neoplasia under the treatment with imatinib. Phan et al. found a higher rate of secondary tumors among GIST patients in the imatinib era than in the pre-imatinib era\(^\text{27}\), although the most likely reason for this is the prolonged survival even of patients with advanced GIST, as it has been described by different authors\(^\text{28}\). Another point that relativizes the impact of imatinib on the development of secondary tumors can be seen in our review: About 75% of associated neoplasias were diagnosed either before GIST or synchronously with GIST; furthermore, not all patients with a GIST diagnosis in advance were treated with imatinib.

In summary, in this, to our knowledge first, systematic review on the topic of secondary neoplasia in patients with GIST, we confirm the previously described elevated number of associated neoplasms and the most common localizations of this neoplasms. We found a higher median age in the GIST with second neoplasm group and significantly more male patients who developed associated tumors, whereas the risk scores of GIST in this group were significantly lower. We conclude that even very low- and low-grade GISTs should be a reason to consider frequent controls or extended staging for early detection of second neoplasias, especially in the gastrointestinal and urogenital tract. To understand whether there is an underlying

---

| Melanoma | [128,129] |
|----------|-----------|
| Squamous Cell Carcinoma | [130] |
| Merkel Cell Carcinoma | [131] |
| Soft Tissue | |
| Myxofibrosarcoma | [82] |
| Dermatofibrosarcoma | [132] |
| Ewing Sarkoma | [133] |
| Others | |
| Adrenocortical Carcinoma | [134] |
| Peritoneal Mesothelioma | [135] |
| Mesenterial Fibromatosis | [136] |
| Granular cell tumor | [55] |

IEN: Intraepithelial neoplasia; SCC: Squamous-cell carcinoma; NET: Neuroendocrine tumor; DLBCL: Diffuse large B cell lymphoma; MALT: Mucosa associated lymphatic tissue; NSCLC: Non-small cell lung cancer.
| Author            | Year | Date of diagnosis | N  | Age average (median) | Sex m/f | Total population | Pat. with ass. NPL | Total population | Pat. with ass. NPL | N of patients with ass. NPL | GI tract | Liver/ gall bladder/ pancreatic | Urogenital tract | Female genital tract | Breast | Blood/ lymphatic system | Head and neck | Lung | Skin/ melanoma | Soft | Other |
|-------------------|------|-------------------|----|----------------------|---------|------------------|-------------------|-------------------|-------------------|-----------------------------|----------|-------------------------------|----------------|------------------------|--------|------------------------|--------|------|---------------|------|------|
| Adim et al [13]   | 2011 | 1997- 2009        | 78 | 62                   | 9/4     | 13               | 9                 | 13 (17%)         |                  |                             | 9        | 2                            | 1                 |                        |        |                         |        |      |               |      |      |
| Agaimy et al [14] | 2005 | 1997- 2004        | 97 | 65                   | 72      | 42/55            | 6/12              | 18 (17%)         |                  |                             | 6        | 3                            | 2                 | 3                      | 2       | 2                | 1     |      |               |      |      |
| Aghdasisi et al [13] | 2018 | 1993- 2011       | 104 | 67                   | 54/50   | 44               |                   | 16 (42%)         |                  |                             | 4        | 8                            | 7                 | 2                      |         | 1                |       |      |               |      |      |
| Amaadour et al [13] | 2013 | 1998- 2006       | 43  | 62                   | 65      | 15/28            | 1/5               | 6 (14%)          |                  |                             | 5        | 5                            |                   |                        |         | 1                |       |      |               |      |      |
| Fernandez et al [13] | 2018 | 1999- 2016       | 104 | 64                   | 62/42   | 22/10            |                   | 32 (31%)         |                  |                             | 9        | 7                            | 3                 | 3                      | 2       | 1                | 1     |      |               |      |      |
| Ferrreira et al [13] | 2010 | 1998- 2006       | 43  | 62                   | 61      | 15/28            | 1/5               | 6 (14%)          |                  |                             | 5        | 5                            |                   |                        |         | 1                |       |      |               |      |      |
| Giuliani et al [13] | 2012 | 2002- 2010       | 24  | 66                   | 69      | 12/12            | 5/3               | 8 (33%)          |                  |                             | 6        | 6                            | 1                 | 1                      |         | 1                |       |      |               |      |      |
| Goncalves et al [13] | 2010 | 1998- 2008       | 101 | 68                   | 5/9     | 14               | 8                 | 14 (14%)         |                  |                             | 2        | 2                            | 1                 | 1                      |         | 1                |       |      |               |      |      |
| Hechtmann et al [13] | 2015 | 2009- 2013       | 260 | 65                   | 142/18  | 30/20            | 50 (19%)          | 21               | 1                 | 8               | 8                 | 7                 | 1             | 3       | 3               | 6     |      |               |      |      |
| Kramer et al [17] | 2015 | 2006- 2011       | 836 | 68                   | 69      | 423/13           | 148/19            | 422 (51%)        |                  |                             | 118      | 20                           | 60                 | 22                     | 26      | 23              | 6     | 8               | 23      | 2    |               | 9     |      |
| Lai et al [13]    | 2016 | 1995- 2015       | 749 | 68                   | 77/59   | 136              | 64 (18%)          | 27               | 12                | 10               | 7                 | 1                 | 9             | 13       | 4               | 3     | 10              |       |      |               |      |      |
| Liszka et al [13] | 2007 | 1989- 2006       | 82  | 64                   | 38/44   | 12/10            | 22 (27%)          | 17               | 5                 | 1               |                   |                   |                        |         | 1                |       |      |               |      |      |
| Mayer et al [13]  | 2019 | 1998- 2017       | 188 | 69                   | 70      | 23               | 1                 | 17 (37%)         | 9                 | 5                 | 5                 | 2               | 5             | 2       | 5               | 3     |      |               |      |      |
| Murphy et al [13] | 2015 | 2001- 2011       | 6112| 3252/ 2860           | 727/81  | 1047             | (17%)             | 208              | 34                | 432              | 144               | 80                | 54             | 99       | 52              | 48    | 72              |       |      |               |      |      |
genetic cause for the elevated rates of GIST-associated neoplasias, further studies will be needed.
### Table 3  Age and sex distribution

|                          | Total study population | GIST with associated neoplasia | No. of patients available for calculation |
|--------------------------|------------------------|-------------------------------|------------------------------------------|
| Age (median)             | 63                     | 68                            | 4176/1139                                |
| Sex male: Female         | 1.1:1                  | 1.4:1                         | 10444/2080                               |

GIST: Gastrointestinal stromal tumors.

### Table 4  Characteristics of gastrointestinal stromal tumors and associated neoplasias

| Parameter                                      | Quantification                                      | No. of patients available for calculation |
|------------------------------------------------|-----------------------------------------------------|------------------------------------------|
| Designation of associated NPL, n (%)           | Benigne 253 (11) Malignant 1995 (89)                | 2248                                     |
| Chronological presentation, n (%)              | Synchronos 366 (50) GIST first 179 (24) Ass. NPL first 187 (26) | 732                                      |
| Histological subtypes of GIST, n (%)           | Spindle Total population 409 (78) GIST + ass. NPL 149 (80) | 525; 185                                |
|                                               | Epitheloid Total population 43 (8) GIST + ass. NPL 11 (6) |                                           |
|                                               | Mixed Total population 73 (14) GIST + ass. NPL 25 (14) |                                           |

GIST: Gastrointestinal stromal tumors.

### Table 5  Distribution of risk scores, n (%)

| Risk score         | GIST without associated neoplasia | GIST with associated neoplasia | Total |
|--------------------|-----------------------------------|--------------------------------|-------|
| Low and very low   | 123 (35)                          | 230 (65)                       | 353   |
| Intermediate and high | 373 (69)                         | 165 (31)                       | 538   |
| Total              | 496                               | 395                            | 891   |

GIST: Gastrointestinal stromal tumors.
ARTICLE HIGHLIGHTS

Research background
In recent years, numerous case reports, mostly retrospective studies and a few reviews on the topic of second neoplasias associated with gastrointestinal stromal tumors (GIST) have been published. To our knowledge, however, this is the first systematic review of the existing data.

Research motivation
The aim of this review was to prepare a compilation, as complete as possible, of all reported second tumor entities that have been described in association with GIST, and to systematically analyze the published studies with regard to frequency, localization, and types of GIST-associated neoplasms.

Research objectives
The main focus of this review was on frequency, localization, dependence of gender, age and risk classification of GIST associated neoplasias. Summarizing the data of a large number of patients could especially help in the daily clinical work with GIST patients.

Research methods
The MEDLINE and EBSCO databases were searched for a combination of the keywords GIST/secondary, synchronous, coincident/tumor, neoplasm, and relevant publications were selected by two independent authors. All case reports were summarized according to the reported tumor entity and included clinical studies were analyzed with regard to the previously mentioned topics.

Research results
Of the initially found 3042 publications, 130 papers were selected; 22 of these were original studies, and 108 were case reports. In the 22 selected studies, comprising a total number of 12050 patients, an overall rate of GIST-associated neoplasias of 20% could be calculated. Most second neoplasias were found in the gastrointestinal tract (32%) and in the male and female urogenital tract (30%). The male-to-female ratio revealed a predominance of male gender in cases with associated neoplasia. The specific risk scores of GISTs associated with other tumors were significantly lower than those of GIST without associated neoplasias. The question if there are specific genetic mutations that occur with a higher frequency in GIST patients with second tumors could not be answered and would be an interesting topic for future research.

Research conclusions
GISTs are associated with other neoplasias with a rate of 20% and occur most frequently in the gastrointestinal and urogenital tract. This confirms previous findings on a larger number of
patients. GIST associated neoplasias occur with a higher likelihood in older, male patients with low grade GIST. 50% of GIST associated neoplasias are detected synchronously. Our findings should be a reason to consider frequent controls or extended staging for early detection of second neoplasias, especially in the gastrointestinal and urogenital tract.

**Research perspectives**

If there is a causal relation between GIST and second tumors remains unclear. As data on genetic second neoplasias, especially in the gastrointestinal and urogenital tract.

**REFERENCES**

1. Soreide K, Sandvik OM, Soreide JA, Giljaca V, Jureckova A, Balusa VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. *Cancer Epidemiol* 2016; 40: 39-46 [PMID: 26618334 DOI: 10.1016/j.canep.2015.10.031]

2. Miettinen M, Lasota J. Gastrointestinal stromal tumours—definition, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch* 2001; 438: 1-12 [PMID: 11213830 DOI: 10.1007/s004280000338]

3. Hirota S, Ioannou K. Pathology of gastrointestinal stromal tumors. *Pathol Int* 2006; 56: 1-9 [PMID: 16398673 DOI: 10.1111/j.1440-1827.2006.01924.x]

4. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary T, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. *Hum Pathol* 2002; 33: 459-465 [PMID: 12094370 DOI: 10.1017/S0018506X02220020]

5. Hirota S, Ioannou K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawanu K, Hanada M, Kozata A, Takeda M, Muhammad Tuo T, Matsumura Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. *Science* 1998; 279: 577-580 [PMID: 9438854 DOI: 10.1126/science.279.5350.577]

6. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. *Nat Rev Cancer* 2011; 11: 865-878 [PMID: 22089421 DOI: 10.1038/nrc3143]

7. Hirota S, Ohashi A, Nishida T, Iozsoki K, Konoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumours. *Gastroenterology* 2003; 125: 660-667 [PMID: 12949711 DOI: 10.1016/S0016-5085(03)01046-1]

8. Rubin BP, Heinrich MC. Genotyping and immunohistochemistry of gastrointestinal stromal tumours: An update. *Semin Diagn Pathol* 2015; 32: 392-399 [PMID: 25766043 DOI: 10.1053/j.semdp.2015.02.017]

9. Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. *Am J Surg Pathol* 2006; 30: 90-96 [PMID: 1630947 DOI: 10.1097/01.pas.0000176433.81079.b3]

10. Carney JA. Carney triad. *Front Horm Res* 2013; 41: 92-110 [PMID: 23625673 DOI: 10.1159/000345472]

11. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Carrel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD. Familial gastrointestinal stromal tumour syndrome: phenotypic and molecular features in a kindred. *J Clin Oncol* 2005; 23: 2735-2743 [PMID: 15837988 DOI: 10.1200/jco.2005.06.009]

12. Murphy JD, Ma GL, Baumgartner JM, Madsen LS, Burgoyne AM, Tang CM, Martinez ME, Sicklick JK. Increased risk of additional cancers among patients with gastrointestinal stromal tumours: A population-based study. *Cancer* 2015; 121: 2960-2967 [PMID: 25930985 DOI: 10.1002/cncr.29434]

13. Smith MJ, Smith HG, Mahar AL, Law C, Ko YJ. The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumours. *Int J Cancer* 2016; 139: 1744-1751 [PMID: 27299364 DOI: 10.1002/ijc.30231]

14. Agaimy A, Wuensch PH. Gastrointestinal stromal tumours in patients with other-type cancer: a mere coincidence or an etiological association? A study of 97 GIST cases. *Langenbecks Arch Surg* 2009; 394: 1-9 [PMID: 18371981 DOI: 10.1007/s00428-009-0338-2]

15. Mayer P, Märkl B, Agaimy A, Krieging B, Dintner S, Schenkirsch G, Schneider-Stock R. Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA. *Pathologe* 2005; 26: 307-314 [PMID: 15993953 DOI: 10.1002/pat.1040]

16. Miettinen M, Lasota J. Gastrointestinal stromal tumours: pathology and prognosis at different sites. *Semin Diagn Pathol* 2006; 23: 70-83 [PMID: 17193820 DOI: 10.1053/j.sdp.2006.09.001]

17. Kramer K, Wolf S, Mayer B, Schmidt SA, Agaimy A, Henne-Bruns D, Knippschild U, Schwab M, Schmieder M, Frequency, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumours. *Neoplasia* 2015; 17: 134-140 [PMID: 25622900 DOI: 10.1016/j.neo.2014.12.001]

18. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Ceryn T, Omlin A. Multiple primary tumours: challenges and approaches, a review. *ESMO Open* 2017; 2: e000172 [PMID: 28761745 DOI: 10.1136/esmoopen-2017-000172]

19. Rheingold SR, Neugut AI, Meadows AT. Secondary cancers: incidence, risk factors, and management. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III, editor. *Holland-Frei Cancer Medicine*. 6th edition. Hamilton: BC Decker, 2003: Chapter 159

20. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumours. *Semin Diagn Pathol* 2006; 23: 120-129 [PMID: 17193825 DOI: 10.1053/j.sdp.2006.09.004]

21. Fernández Hernández JA, Olivares Ripoll V, Parrilla Paricio P. [Additional primary malignancies in patients with gastrointestinal stromal tumours. Proposal for a new classification]. *Med Clin (Barc)* 2016; 147: 405-409 [PMID: 27431866 DOI: 10.1016/j.medcli.2016.06.006]

22. Núñez-Martin R, Cubedo Cervera R, Provencio Palla M. Gastrointestinal stromal tumour and second tumours: A literature review. *Med Clin (Barc)* 2017; 149: 345-350 [PMID: 28736068 DOI: 10.1016/j.medcli.2017.06.010]

23. Burgoyne AM, Somaiah N, Sicklick JK. Gastrointestinal stromal tumours in the setting of multiple tumour syndromes. *Curr Opin Oncol* 2014; 26: 408-414 [PMID: 24840526 DOI: 10.1097/GOO.0000000000000172]
Waidhauser J et al. GIST associated neoplasia

10.1097/CCO.0000000000000089

24 Giuliani J, Bonetti A. The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies. J Gastrointestin Liver Dis 2010; 19: 204-211 [PMID: 20381123 DOI: 10.1016/j.jgld.2009.11.017]

25 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

26 Artiyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhor ND. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev 2008; 17: 2194-2201 [PMID: 18780414 DOI: 10.1158/1055-9966.EPI-08-0237]

27 Phan K, Martinez K, Kurlander DE, Gaddipati K, Xavier M. The incidence of second primary malignancies after gastrointestinal stromal tumor before and after the introduction of imatinib mesylate. TCR 2013; 3: 152-159 [DOI: 10.3978/j.issn.2218-676X.2013.03.07]

28 Giuliani J, Bonetti A. Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate. Chin J Cancer Res 2013; 25: 486-487 [PMID: 24255568 DOI: 10.3978/j.issn.1000-9604.2013.10.13]

29 Cinar H, Topgil O, Kesciglioglu T, Can B, Koca B, Karabacak I, Ozbalci GS. Synchronous primary adenocarcinoma and gastrointestinal stromal tumor in the stomach. Haseki Tip Bulenti 2014; 52: 50-52

30 Jeong SH, Lee YJ, Park ST, Choi SK, Hong SC, Jung JE, Ju YT, Jeong CY, Ha WS. Synchronous Adenocarcinoma and Gastrointestinal Stomatal Tumor of the Stomach Treated by a Combination of Laparoscopy-assisted Distal Gastrectomy and Wedge Resection. J Gastric Cancer 2011; 11: 55-58 [PMID: 22076202 DOI: 10.5230/jgc.2011.11.1.55]

31 Kleist B, Lasota J, Murtmten M. Gastrointestinal stromal tumor and gastric adenocarcinoma collision tumors. Hum Pathol 2010; 41: 1034-1039 [DOI: 10.1016/j.humpath.2009.11.017]

32 Kountourakis P, Amogiannakis N, Stavriniides I, Apostolakis N, Rigatos G. Concomitant gastric adenocarcinoma and stromal tumor in a woman with polymyalgia rheumatica. World J Gastroenterol 2008; 14: 6750-6752 [PMID: 1903494]

33 Kycker W, Teresiak M, Lozinski C. A case of multi-focus gastric adenocarcinoma occurring synchronously with an associated gastric GIST. Pract Radiol 2006; 11: 97-100

34 Lee FY, Jan YJ, Wang J, Yu CC, Wu CC. Synchronous gastric gastrointestinal stromal tumor and signet-ring cell adenocarcinoma: a case report. Int J Surg Pathol 2007; 15: 397-400 [PMID: 17913950 DOI: 10.1177/1066896907302369]

35 Moran M, Bilgic I, Dilekstasi E, Albayrak L, Oruc MT, Ozmen MM. Synchronous tumors of the stomach: A case report of mixed gastrointestinal stromal tumor and adenocarcinoma. Turk Geriatri Dergisi 2010; 13: 125-128

36 Munekage E, Namikawa T, Kawanishi Y, Munekage M, Maeda H, Kitagawa H, Sakamoto K, Ohbatake M, Kobayashi M, Hanazaki K. Synchronous large gastrointestinal stromal tumor and adenocarcinoma in the stomach treated with imatinib mesylate followed by total gastrectomy. J Gastroenterol Hepatol (Australia) 2016; 31 Suppl: 106-107

37 Narasirimahurthy MS, Vallachira GP, Mahadev PS. Synchronous adenocarcinoma and gastrointestinal stromal tumor in the stomach. Saudi J Gastroenterol 2010; 16: 218-220 [PMID: 20616420 DOI: 10.4103/1319-3767.65190]

38 Athanasio E, Vamvakopoulou DN, Zacharoudis D, Paroutougou G, Siotiapoulou D, Tepetes K, Nomikos I, Vamvakopoulou NC. Immunohistochemical evaluation of DNA mismatch repair defect in tumors of synchronous histomorphologically distinct gastric adenocarcinomas with gastrointestinal stromal tumors of the proximal small bowel. Appl Immunohistochem Mol Morphol 2010; 18: 288-290 [PMID: 20995515 DOI: 10.1097/PAI.0b013e3181ca8d8d]

39 Fan H, Lu P, Xu L, Yin Y, Li J. Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report. BMC Cancer 2017; 17: 720 [PMID: 29115925 DOI: 10.1186/s12885-017-3736-6]

40 Kalender ME, Sevince A, Kucukdemir Z, Balkic A, Sari I, Cemel C. Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor. Onkolgie 2007; 30: 568-570 [PMID: 17992028 DOI: 10.1159/000108604]

41 Ozgun YM, Ergul E, Sisman IC, Kusdemir A. Gastric adenocarcinoma and GIST (collision tumors) of the stomach: a case report. Int J Surg Pathol 2009; 17: 44-47 [PMID: 19124669 DOI: 10.1177/1066896907302369]

42 Sista F, Abruzzese V, Schietroma M, Amicucci G. Concomitant gastrointestinal stromal tumor and adenocarcinoma of the stomach and gastric adenocarcinoma in a patient with bilirubin 2 resection. Case Rep Surg 2013; 2013: 583856 [PMID: 24455386 DOI: 11.1155/2013/583856]

43 Telugu RB, Pushpajar M, Masih D, Pulimood A. Synchronous Appearance of Adenocarcinoma and Gastrointestinal Stromal Tumours (GIST) of the Stomach: A Case Report. J Clin Diagn Res 2016; 10: ED16-ED18 [PMID: 27042477 DOI: 10.7860/JCOD/2016/17636.7299]

44 Theodosopoulos T, Dellaportas D, Psychogiou V, Gennatas K, Kordis-Pafiti A, Gkiokas G, Papaconstantinou I, Polymeneas G. Synchronous gastrointestinal stromal tumor and adenocarcinoma of the stomach: a case report. Int J Surg Pathol 2011; 19: 152-159 [DOI: 10.1177/1066896907302369]

45 Uchiyama S, Nagano M, Takahashi N, Hidaka H, Matsuda H, Nagaki K, Maehara N, Hotokezaka M, Chijiwa K. Synchronous adenocarcinoma and gastrointestinal stromal tumors of the stomach treated laparoscopically. Int J Clin Oncol 2007; 2: 478-481 [PMID: 18071869 DOI: 10.1007/s10147-007-0684-8]

46 Villas C, Gourgiotis S, Velouidis G, Sampaziotis D, Moreas H. Synchronous early gastric cancer and gastrointestinal stromal tumor in the stomach of a patient with idiopathic thrombocytopenic purpura. J Dig Dis 2008; 9: 104-107 [PMID: 18419644 DOI: 10.1111/j.1751-2980.2008.00330.x]

47 Vogel Y, Muller C, Uhl W, Tanamplp A. [Coexistence of multifocal gastric adenocarcinoma with signet-ring cell morphology and a gastrointestinal stromal tumour in a stomach with hp-associated gastritis]. Z Gastroenterol 2011; 49: 201-206 [PMID: 21208606 DOI: 10.1055/s-0030-1245593]

48 Zhou Y, Wu XD, Shi Q, Jia J. Coexistence of gastrointestinal stromal tumor, esophageal and gastric cardia carcinomas. World J Gastroenterol 2013; 19: 2005-2008 [PMID: 23569349 DOI: 10.3748/wjg.v19.i12.2005]

49 Salesin MS, Gourgiotis S, Tsiambas E, Karameris A, Tsotharidis E. Synchronous occurrence of advanced adenocarcinoma with a stromal tumor in the stomach: a case report. J Gastrointest Liver Dis 2008; 17: 213-215 [PMID: 18568146]
Kaffes A, Hughes L, Hollinshead J, Katelaris P. Synchronous primary adenocarcinoma, mucosa-associated lymphoid tissue lymphoma and a stromal tumor in a Helicobacter pylori-infected stomach. J Gastroenterol Hepatol 2002; 17: 1033-1036 [PMID: 12167128]

Yamamoto D, Hamada Y, Tsubo Y, Kawakami K, Yamamoto C, Yamamoto M. Simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) in the stomach: case report. World J Surg Oncol 2012; 10: 6 [PMID: 22209394 DOI: 10.1186/1477-7819-10-6]

Lin YL, Tseng JE, Wei CK, Lin CW. Small gastrointestinal stromal tumor concomitant with early gastric cancer: a case report. World J Gastroenterol 2006; 12: 815-817 [PMID: 16521203]

Chen JJ, Chen CC, Tseng LM, Tsay SH, Chiang HJ, Lu CC, Chang FY, Lee SH. Resection of triple synchronous tumors—gastric adenocarcinoma, gallbladder adenocarcinoma and stromal tumor of the stomach. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64: 655-660 [PMID: 11833211]

Bircan S, Candri O, Aydin S, Baspinar S, Bülbül M, Kapucuoğlu N, Karahan N, Ciriç M. Synchronous primary adenocarcinoma and gastrointestinal stromal tumor in the stomach: a report of two cases. Turk J Gastroenterol 2008; 15: 187-191 [PMID: 15499290]

Sailors JL, French SW. The unique simultaneous occurrence of granulocellular tumor, gastrointestinal stromal tumor, and gastric adenocarcinoma. Arch Pathol Lab Med 2005; 129: e121-e123 [PMID: 15859658 DOI: 10.1043/1543-2165(2005)129:0.CO:2]

Chiu HH, Huang TC, Liu YW, Ko TL, Lu NK. Synchronous ileal stromal tumor (GIST) and colonic adenocarcinoma. J Int Med Taiwan 2009; 20: 266-263

Dimitroulopoulos D, Fotopoulou A, Xinopoulos D, Armogianni K, Korkolis D, Tsmakidis K, Kypros D, Bassioukas S, Patsavela S, Paraskevas E. Synchronous occurrence of colorectal adenocarcinoma and colorectal gastrointestinal stromal tumor (GIST). A case report. Ann Gastroenterol 2009; 22: 197-200

Efstratiou P, Athanasios P, Papacostantinou I, Alexandros P, Franjiska S, Sotirios G, Evangelos F, Athanasios G. Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: A case report. World J Surg Oncol 2007; 5: 96 [PMID: 17708776 DOI: 10.1186/1477-7819-5-96]

Firat O, Yazici P, Makay O, Aydin A, Tuncyurek M, Ersin S, Guler A. Co-existence of gastrointestinal stromal tumors with malignant epithelial tumors: a report of two cases. Acta Chir Belg 2009; 109: 629-632 [PMID: 19994809]

Gavrilidis P, Nikolaidou A. Colon Adenocarcinoma Associated with Synchronous Extramural Gastrointestinal Stromal Tumor (GIST) of the Ileum. Am J Case Rep 2015; 16: 837-839 [PMID: 26606826]

Jafferbhoy S, Paterson H, Finzron P. Synchronous gist, colon and breast adenocarcinoma with double colonic polyph metastases. Int J Case Rep 2014; 5: 523-526 [PMID: 25014550 DOI: 10.1016/j.ijscr.2014.04.020]

Kosmidis C, Ellithimidis C, Lefva S, Anthimidis G, Baka S, Grigoriou M, Tzeveleki I, Masanidou M, Zarambouskas T, Basdanis G. Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor in Meckel's diverticulum; an unusual association. World J Surg Oncol 2009; 7: 33 [PMID: 19309481 DOI: 10.1186/1477-7819-7-33]

Marković M, Jurišić V, Petrović M, Dagović A, Stanković V, Mitrović S. Appearance of ductal breast and colon carcinoma with gastrointestinal stromal tumor (GIST) in a female patient: an extremely rare case. Rom J Morphol Embryol 2018; 59: 613-617 [PMID: 30173272]

Molis M, Choi EA, Anders R, Christiansen P, Fichera A. Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST). Int J Colorectal Dis 2007; 22: 109-114 [PMID: 16639564 DOI: 10.1007/s00384-006-0089-6]

Nemes C, Rogorjan L, Surdeanu-Blaga T, Seicean A, Dumitrascu DL, Cucea C. Gastrointestinal stromal tumor (GIST) associated with synchronous colon adenocarcinoma - a case report. J Gastrointestin Liver Dis 2012; 21: 101-103 [PMID: 22457667]

Dragan R, Dejan S, Nebojsa M, Vinka V, Predrag S, Dragoljub B. Synchronous appearance of gastric gastrointestinal stromal tumors and colorectal adenocarcinoma: a case report. Hepatogastroenterology 2011; 58: 2171-2174 [PMID: 22234087 DOI: 10.5754/hge09042]

Kaur R, Bhalia S, Nundy S, Jain S. Synchronous gastric gastrointestinal stromal tumor (GIST) and other primary neoplasms of gastrointestinal tract: report of two cases. Ann Gastroenterol 2013; 26: 356-359 [PMID: 24714328]

Seshadri RA, Singh SS, Ratnagiri R. Synchronous jejunal gastrointestinal stromal tumor and primary adenocarcinoma of the colon. Indian J Surg 2012; 74: 196-198 [PMID: 23543778 DOI: 10.1007/s12262-011-0226-3]

Suzuki T, Sawu K, Hanya K, Okamoto T, Fujita T, Yanaga K. Large gastrointestinal stromal tumor and advanced adenocarcinoma in the rectum coexistent with an incidental prostate carcinoma: A case report. Int J Surg Case Rep 2014; 5: 640-642 [PMID: 25052916 DOI: 10.1016/j.ijscr.2014.06.012]

Traidjukova E, Janevska V, Spasevska L, Janevski V, Zhivadinovik J, Petrushevska G, Dukova B. Synchronous occurrence of ileal stromal tumor (GIST) and colonic adenocarcinoma: a case report. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2015; 216: 229-233 [PMID: 26076794]

Kumar K, Rowseil C, Law C, Ko YJ. Coexistence of gastrointestinal stromal tumour and colorectal adenocarcinoma. Two case reports. J Gastrointest Oncol 2011; 2: 50-54 [PMID: 22811828 DOI: 10.9708/jso.2011.2.2.502978]

Mou YP, Xu XW, Xie K, Zhou W, Zhou YC, Chen K. Laparoscopic wedge resection of synchronous gastric intraepithelial neoplasia and stromal tumor: a case report. World J Gastroenterol 2010; 16: 5005-5008 [PMID: 20954290]

Spinelli GP, Miele E, Tomao F, Rossi L, Panciuti G, Zullo A, Zoratto F, Nunnari J, Pisaneli GC, Tomao S. The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site. World J Surg Oncol 2008; 6: 116 [PMID: 18965377 DOI: 10.1186/1477-7819-6-116]

Alkaakia A, Abdulhadi B, Alijiffy M, Nassif M, Al-Maghbrabi H, Maghrabi AA. Coexistence of Primary GEI Adenocarcinoma and Pedunculated Gastric Gastrointestinal Stromal Tumor. Case Rep Surg 2018; 2018: 4378368 [PMID: 29920977 DOI: 10.1155/2018/4378368]

Grigor'eva VD, Gulaeva EN. [The combined use of dry-air carbon dioxide baths and applications of peolida at low temperatures in the rehabilitation of patients with psoriatic arthritis]. Vopros Kureritol Fizioter Lech Fiz Kult 1998; 25-28 [PMID: 9560999 DOI: 10.1167/S1607-551X(99)07052-5]

Blandamura S, Alessandrini L, Bertorelle R, Simonato F, Guzzardo V, Valentini E, Angriman I, Fassina A. Multiple sporadic gastrointestinal stromal tumours concomitant with amputation adenocarcinoma: a case report with KIT and PDGFRA mutation analysis and miR-221/222 expression profile. Pathol Res Pract 2014; 210: 392-396 [PMID: 24674454 DOI: 10.1016/j.prp.2014.01.019]
77 Koer NE, Kayaselcuk F, Calisirkan K, Ususan S. Synchronous GIST with osteoblast-like giant cells and a well-differentiated neuroendocrine tumor in Ampulla Vateri: coexistence of two extremely rare entities. *Pathol Res Pract* 2007; 203: 667-670 [PMID: 17656040 DOI: 10.1016/j.prp.2007.04.012]

78 Al-Brabih N, Radhi J, Gately J. Synchronous epithelioid stromal tumour and lipoma in the stomach. *Can J Gastroenterol* 2003; 17: 374-375 [PMID: 12813603 DOI: 10.1155/2003/63790]

79 Cirillo F. Neuroendocrine tumors and their association with rare tumors: observation of 4 cases. *Eur Rev Med Pharmacol Sci* 2010; 14: 577-588 [PMID: 20707247]

80 Ding J, Sun P, Cai XY, Fei SH, Wu J, Qi YK, Liu ZB, Yuan L, He VJ, Song H, Chen WX. Synchronous poorly-differentiated neuroendocrine carcinoma and gastrointestinal stromal tumor of the stomach: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFβRA. *Int J Clin Exp Pathol* 2014; 7: 9076-9080 [PMID: 25674291]

81 Samaras DV, Foukas PG, Triantafyllou K, Leontara V, Tsapralis D, Tsompanidi EM, Machairas A, Panayiotides IG. Synchronous well-differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report. *BMC Gastroenterol* 2011; 11: 27 [PMID: 21452252 DOI: 10.1186/1471-230X-11-27]

82 Tan E, Friedman M, Coppola D. Occurrence of Multiple Tumors in a Patient. *Cancer Control* 2015; 22: 505-507 [PMID: 26687987 DOI: 10.17707/10732748.502200417]

83 Buragas M, Kidd M, Modlin IM, Cha C. Multiple gastrointestinal stromal tumors and synchronous ileal carcinoids. *Nat Clin Pract Oncol* 2005; 2: 166-70, quiz 1 p following 170 [PMID: 16264910 DOI: 10.1038/ncpnaco0108]

84 Cho H, Watanabe T, Aoyama T, Hayashi T, Yamada T, Ogata T, Yoshikawa T, Tsusabura A, Sekiguchi H, Nakamura Y, Sakuma Y, Kameda Y, Miyagi Y. Small bad of probable gastrointestinal stromal tumor within a laparoscopically-resected gastric schwannoma. *Int J Clin Oncol* 2012; 17: 294-298 [PMID: 21850386 DOI: 10.1007/s10147-011-0296-1]

85 Amoroso M, Papagi N, Picciariello A, Pinto VL, D’Abbiggio D, Margari A. Intestinal occlusion by stenotic neuroendocrine tumors of left colon and concomitant association with small bowel gastrointestinal stromal tumors: A case report. *Int J Surg Case Rep* 2018; 53: 182-185 [PMID: 30408742 DOI: 10.1016/j.ijscr.2018.10.034]

86 Pata F, Sengodan M, Tang CB, Kadirkamanathan SS, Harvey M, Zaitoun A, Petkar M, Rotundo A. Concomitant jejunal sarcomatoid carcinoma and gastric GIST in patient with polymyalgia rheumatica: A case report. *Int J Surg Case Rep* 2013; 4: 449-452 [PMID: 23548706 DOI: 10.1016/j.ijscr.2013.02.007]

87 Dasanu CA. Mesolobites T, Trikudanathan G. Synchronous tumors: adenosquamous carcinoma of pancreas and GIST of stomach: *J Gastrointest Cancer* 2011; 42: 186-189 [PMID: 20623381 DOI: 10.1007/s10212-009-0197-3]

88 He JJ, Ding KF, Zheng L, Xu JH, Li J, Wu YL, Sun LF, Zhou DE, Zheng S. Adenosquamous carcinoma of the uncinate process of the pancreas with synchronous gastrointestinal stromal tumor of the stomach: Case report and review of the literature. *Oncol Lett* 2012; 4: 1191-1194 [PMID: 23179797 DOI: 10.3892/ol.2012.902]

89 Fiore M, de Stefano G, Coppola N, Giorgio A. Synchronous and metachronous gastric metastasis with gastric adenocarcinoma: report of 2 cases and a review of literature. *Gastroenterol Hepatol Bed Bench* 2015; 8: 298-301 [PMID: 26463351]

90 Shen ZL, Wang S, Ye YJ, Wang YL, Sun KK, Yang XD, Jiang KW. Carcinosarcoma of pancreas with liver metastasis combined with gastrointestinal stromal tumor of the stomach: is there a good prognosis with the complete resection? *Eur J Cancer Care (Eng)* 2010; 19: 118-123 [PMID: 19486125 DOI: 10.1111/j.1365-2354.2008.00977.x]

91 Arabadzhieva E, Yonkov A, Bonev S, Bulanov D, Taneva I, Vlahova A, Dimitrova V. A rare case of synchronous gastrointestinal stromal tumor, pancreatic neuroendocrine tumor, and heterotopic islet cell adenomas. *World J Surg Oncol* 2016; 14: 287 [PMID: 27846844 DOI: 10.1186/s12957-016-0515-x]

92 Tavares AB, Viveiros FA, Cidade CN, Maciel J. Gastric GIST with synchronous neuroendocrine tumour of the pancreas in a patient without neurofibromatosis type 1. *BMJ Case Rep* 2012; 2012: bcr2012023893 [PMID: 22671144 DOI: 10.1136/bcr-2012-023893]

93 Ueda K, Hijoksa M, Lee L, Igarashi H, Niina Y, Oseogawa T, Nakamura K, Takahashi S, Aishima S, Ohtsuka T, Takayanagi R, Ito T. A synchronous pancreatic neuroendocrine tumor and duodenal gastrointestinal stromal tumor. *Intern Med* 2014; 53: 2483-2488 [PMID: 25366070]

94 Alabraba E, Bramhall S, OSullivan B, Mahon B, Taniere P. Pancreatic insulinoma co-existing with gastric GIST in the absence of neurofibromatosis-1. *World J Surg Oncol* 2009; 7: 18 [PMID: 19216788 DOI: 10.1186/1477-7819-7-18]

95 Haugevik SP, Rasok BI, Edwin B, Gladhaug IP, Mathisen Ø. Concomitant Nonfunctional Pancreatic Neuroendocrine Tumor and Gastric GIST in a Patient Without Neurofibromatosis Type 1. *J Gastrointest Cancer* 2012; 43 Suppl 1: S171-S174 [PMID: 22083533 DOI: 10.1007/s12952-011-9344-3]

96 Felekouras E, Athanasios P, Vgenopoulos S, Papakonstantinou I, Prassas E, Giannopoulos A, Gnintanos J. Coexistence of hepatocellular carcinoma (HCC) and e-KIT negative gastrointestinal stromal tumor (GIST): a case report. *South Med J* 2008; 101: 948-951 [PMID: 18708966 DOI: 10.1097/SMJ.0b013e31817f027b]

97 Ferreira E, Mora H, Pinto de Sousa J, Devesa V, Barbosa J, Costa J, Portugal R, Costa-Maia J. Gastrintestinal stromal tumor of the stomach and hepatocellular carcinoma: An unusual association. *Int J Surg Case Rep* 2015; 12: 75-77 [PMID: 26028680 DOI: 10.1016/j.ijscr.2015.05.020]

98 Yamashita K, Baba Y, Kurashige J, Iwatsuki M, Imai K, Hashimoto D, Sakamoto Y, Chikamori A, Yoshida N, Beppu T, Baba H. Co-occurrence of liver metastasis of gastrointestinal stromal tumor and hepatocellular carcinoma: a case report. *Surg Case Rep* 2016; 2: 86 [PMID: 25786263 DOI: 10.1016/j.ijscr.2015.06.012]

99 Jaworski R, Jastrzebski T, Swierblewski M, Drucis K, Kobierska-Gulida G. Coexistence of hepatocellular carcinoma and gastrointestinal stromal tumor: a case report. *World J Gastroenterol* 2006; 12: 665-667 [PMID: 16489690]

100 Mrzdaj A, Koluta I, Skrétí K, Kardum-Skelin I, Vrhovac R. Metachronous gastrointestinal stromal tumor and acute leukemia after liver transplantation for cholangiocellular carcinoma: is there a link? *Case Rep Oncol* 2013; 6: 163-168 [PMID: 23626555 DOI: 10.1159/000348817]

101 Nam SJ, Choi HS, Kim ES, Keum B, Jee YT, Chun HJ. Synchronous occurrence of gastrointestinal stromal tumor and intrahepatic cholangiocarcinoma: A case report. *Oncol Lett* 2015; 9: 165-168 [PMID: 25435922 DOI: 10.3892/ol.2014.2703]

102 Paiva CE, Morige Neto FA, Agaimy A, Custodio Domingues MA, Rogatto SR. Perivascular epithelioid
cell tumor of the liver coexisting with a gastrointestinal stromal tumor. *World J Gastroenterol* 2008; 14: 800-802 [PMID: 18205275]

103. Gundes E, Kucukkartalir T, Colak MH, Kartal A, Esen HH. Gastrointestinal stromal tumor in the stomach co-existent with renal cell carcinoma. *Erciyes Tip Dergisi* 2014; 36: 47-50

104. Torous VF, Su A, Lu DY, Dry SM. Adult Patient with Synchronous Gastrointestinal Stromal Tumor and Xp11 Translocation-Associated Renal Cell Carcinoma: A Unique Case Presentation with Discussion and Review of Literature. *Case Rep Urol* 2015; 2015: 814809 [PMID: 26246933 DOI: 10.1155/2015/814809]

105. Jiang Q, Zhang Y, Zhou YH, Hou YY, Wang JY, Li JL, Li M, Tong HX, Lu WQ. A novel germline mutation in SDH4 identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. *Int J Clin Exp Pathol* 2015; 8: 12188-12197 [PMID: 26722403]

106. Comandini D, Damiani A, Pastorino A. Synchronous GISTs associated with multiple sporadic tumors: a case report. *Drugs Context* 2017; 6: 212307 [PMID: 29167690 DOI: 10.7573/212307]

107. Rebecga LF, Pátraçu A, Miron D, Dumitru ME, Finescu D. Metachronous gastrointestinal stromal tumor associated with other neoplasia - case presentation. *Rom J Morphol Embryol* 2016; 57: 1429-1435 [PMID: 28174815]

108. Favero G, Pifferi T, Riedlinger WF, Chiantera V, Schneider A. Uncommon synchronous association between ovarian carcinoma and gastrointestinal stromal tumor: a case study and literature review. *Tumori* 2015; 99: e270-e272 [PMID: 23748833 DOI: 10.1700/1238.14211]

109. Li W, Wu X, Wang N, Yin D, Zhang SL. Gastrointestinal stromal tumor in a patient with synchronous isolated parenchymal metastasis of ovarian cancer. *Chin Med J (Engl)* 2011; 124: 4372-4375 [PMID: 22340459]

110. Damiani GR, Coco L, Monfreda L, Guatelli M, Barnaba M, Germinario S, Lovergo G. A rare case of coexistence of ovarian cancer and gastrointestinal stromal tumor. *Giornale Italiano di Ostetricia e Ginecologia* 2011; 33: 255-258

111. Sharma MB, Bhat AD, Padur K, Singh K, Singh BS, Singh SC. Spontaneous Perforation as a First Presentation of Intestinal Gastrointestinal Stromal Tumour (GIST) with Synchronous Breast Carcinoma. *J Clin Diagn Res* 2014; 8: ND07-ND09 [PMID: 24995213 DOI: 10.7860/JCDR/2014/729441]

112. Joo YB, Choi SH, Kim SK, Shim B, Kim MS, Kim YJ. Synchronous development of KIT positive acute myeloid leukemia in a patient with gastrointestinal stromal tumor. *Korean J Hematol* 2010; 45: 66-69 [PMID: 21120166 DOI: 10.5045/kjh.2010.45.1.66]

113. Gao NA, Guo NJ, Yu WZ, Wang XX, Sun JR, Yu N, Liu RT, Liu XD, Liu ZY, Feng R. Synchronous occurrence of gastrointestinal stromal tumor and acute myeloid leukemia: A case report and review of the literature. *Oncol Let* 2016; 11: 2977-2980 [PMID: 27123049 DOI: 10.3392/ol.2016.4537]

114. Sonmez M, Arslan M, Cobanoglu U, Kavgarci H, Ozbas HM, Aydin F, Ovahi E, Omay SB. Association of gastrointestinal stromal tumor and acute myeloid leukemia preceded by myelodysplastic syndrome with refractory anemia. *Tumori* 2009; 95: 240-242 [PMID: 19579873]

115. Herbers AH, Keuning JJ. Staging for LLN-type non-Hodgkin’s lymphoma reveals a gastrointestinal stromal tumour. *Neth J Med* 2005; 63: 74-75 [PMID: 15766012]

116. Pamukcuoglu M, Budakoglu B, Han O, Tad M, Oksuzoglu B, Abali H, Zengin N. An extraordinary case in whom gastrointestinal stromal tumor and low-grade malignant lymphoma are seen together in the stomach. *Med Oncol* 2007; 24: 351-353 [PMID: 17873313]

117. Ludmir EB, Gutscheittner T, Pinncx CC, Gunther JR, Nastoupil LJ, Diede MJ, Medeiros LJ, Dabaja BS, Milgrom SA. Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. *Onco Targets Ther* 2018; 11: 8937-8942 [PMID: 30573980 DOI: 10.2147/OTT.S159843]

118. Takahashi T, Maruyama Y, Saitoh M, Itoh H, Yoshimino M, Tsujsiaki M, Nakayama M. Synchronous Occurrence of Diffuse Large B-cell Lymphoma of the Duodenum and Gastrointestinal Stromal Tumor of the Ileum in a Patient with Immune Thrombocytopenic Purpura. *Intern Med* 2016; 55: 2951-2956 [PMID: 27746431 DOI: 10.2169/internalmedicine.55.6712]

119. Au WY, Wong WM, Khoi US, Liang R. Challenging and unusual cases: Case 1. Concurrent gastrointestinal stromal tumor and Burkitt's lymphoma. *J Clin Oncol* 2003; 21: 1417-1418 [PMID: 12663777 DOI: 10.1200/jco.2003.05.181]

120. Rahimi K, Gologan A, Haliotis T, Lamoureux E, Chetty R. Gastrointestinal stromal tumor with autonomic nerve differentiation and coexistent mantle cell lymphoma involving the appendix. *Int J Clin Exp Pathol* 2008; 2: 608-613 [PMID: 19363371]

121. Salar A, Ramon JM, Barranco C, Nieto M, Prats M, Serrano S, Besses C. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 1. Synchronous mucosa-associated lymphoid tissue lymphoma and gastrointestinal stromal tumors of the stomach. *J Clin Oncol* 2005; 23: 7221-7223 [PMID: 16192606 DOI: 10.1200/jco.2005.08.158]

122. Tzilves D, Gatsopoulou A, Zervas K, Katoiriou E, Patakisouta F, Tarpagos A, Katsos I. Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report. *World J Gastroenterol* 2007; 13: 2011-2013 [PMID: 17461509]

123. Nagaiki M, Joosum Y, Nomura J, Iimi M, Tagawa T. A case of double cancer involving oral malignant melanoma and gastrointestinal stromal tumor (GIST). *Int J Oral Maxillofac Surg* 2005; 34: 328-330 [PMID: 15741044 DOI: 10.1016/j.ijom.2004.06.008]

124. Arsojannikni N, Mitzoukou I, Koutouarakis P, Dimitriadis E, Papapathanasi K, Nastoulis E, Gazalidou M, Fida A, Apostolokas N, Agnantis BJ. Synchronous presentation of GISTs and other primary neoplasms: a single center experience. *In Vivo* 2010; 24: 109-115 [PMID: 2033985]

125. Miyoshi T, Mori R, Amano S, Sumitomo K, Aoyama M, Inoue S, Hino N, Wada D. Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report. *J Med Invest* 2016; 63: 144-148 [PMID: 27040071 DOI: 10.2152/jmi.63.144]

126. Jiang MJ, Weng SS, Cao Y, Li XF, Wang LH, Xu JH, Yuan Y. Metachronous Primary Adenocarcinoma of Lung During Adjuntant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report. *Medicine (Baltimore)* 2015; 94: e146 [PMID: 26356712 DOI: 10.1097/md.000000000001484]

127. Wada Y, Koizumi T, Yokoyama T, Urushihata K, Yamamoto H, Hanoaka M, Kubo K. Synchronous gastrointestinal stromal tumor and primary lung adenocarcinoma. *Intern Med* 2012; 51: 2407-2410 [PMID: 22975558 DOI: 10.2169/internalmedicine.51.7888]

128. Brummel N, Awaal Z, Frazier S, Liu J, Rangnekar N. Perforation of metastatic melanoma to the small bowel with simultaneous gastrointestinal stromal tumor. *World J Gastroenterol* 2005; 11: 2687-2689
Synthetic drug and possible new toxicity - Squamous cell carcinoma following melanoma survivor: A case report. J Am Acad Dermatol 2017; 76: 621-624 [PMID: 28535848 DOI: 10.1016/j.jaad.2016.07.027]

Wollina U, Wang T, Humpf HU, Bader D. Merkel cell carcinoma of the lower leg in a melanoma survivor: A case report. Int J Dermatol 2009; 48: 89-91 [PMID: 19040511 DOI: 10.1111/j.1365-4632.2008.04188.x]

August 14, 2019 | Volume 25 | Issue 30 | WJG | https://www.wjgnet.com
Sevinc A, Seker M, Bilici A, Ozdemir NY, Yildiz R, Ustaalioglu BO, Kalender ME, Dane F, Karaca H, Gemici C, Gumus M, Buyukberber S. Co-existence of gastrointestinal stromal tumors with other primary neoplasms. *Hepatogastroenterology* 2011; 58: 824-830 [PMID: 21830398]

Vassos N, Agaimy A, Hohenberger W, Croner RS. Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: prognostic implications. *Int J Surg* 2014; 12: 371-377 [PMID: 24632413 DOI: 10.1016/j.ijsu.2014.03.004]
